In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreType(s) of biological therapy-Brentuximab Vedotin Posts on Medivizor
Searching for patients with Epstein-Barr positive lymphoma to test a new therapy
In a nutshell This study is investigating the effectiveness of T-cell immunotherapy in Hodgkin’s lymphoma (HL) patients with tumors that are EBV+ (positive for Epstein-Barr virus). This study is recruiting in Duart, California, Washington, D.C., Baltimore, New York, Pittsburgh, and Houston. The details It is thought that individuals who have...
Read MoreBrentuximab vedotin: a study of its safety for unresponsive Hodgkin lymphoma.
In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...
Read MoreDoes anti-PD1 therapy change the effectiveness of chemotherapy in unresponsive Hodgkin lymphoma?
In a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...
Read MoreWhat are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read MoreHow safe and effective is combined brentuximab vedotin and bendamustine in patients with relapsed/refractory HL?
In a nutshell This study determined the safety and effectiveness of combined brentuximab vedotin (Adcetris) and bendamustine (Treanda) for relapsed or refractory (did not respond to treatment) Hodgkin’s lymphoma (HL). The study concluded that this combination is safe and effective, even for patients who already received intense anticancer...
Read MoreUse of brentuximab vedotin, nivolumab, and pembrolizumab for treating patients with relapsed or refractory Hodgkin lymphoma
In a nutshell This study looked at the use of brentuximab vedotin (Adcetris), nivolumab (Opdivo), and pembrolizumab (Keytruda) in treating patients with relapsed or refractory Hodgkin lymphoma. The study concluded that all three medications are very effective at treating patients with relapsed or refractory Hodgkin lymphoma. Some...
Read MoreThe real-world effectiveness of brentuximab vedotin
In a nutshell This study looked at the effects of brentuximab vedotin (Adcetris) in a real-world setting. The study concluded that this is a valid treatment for patients with relapsed Hodgkin lymphoma, and is especially helpful in elderly patients. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However,...
Read More